ACC 2023 | Ultrasensitive Troponin I Monitoring with a Transdermal Wrist Device

Over the years, early diagnosis of myocardial ischemia has ranged from 0-to-3-h protocols to abbreviated guidelines with point-of-care cardiac marker dosing. However, specific devices for this have not yet been validated.

The Sengupta P. et al. research group evaluated the feasibility of using an infrared measuring device—placed on the wrist of patients—compared with blood sampling for conventional cardiac marker dosing.

A multicenter, observational study was conducted to predict elevated circulating Troponin I (TI-us) looking to correlate these photometry data with machine learning models. Patients with angina and ECG suggestive of acute coronary syndrome (ACS) were included.

The primary training endpoint of the machine learning model was the presence of elevated troponin, correlated with both methods.

Read also: ACC 2023 | PULSE-AF.

A biochemical validation was conducted, showing an area under the curve of 0.92, with a sensitivity of 0.94 and a specificity of 0.64. In the unadjusted analysis, an elevated TI-us result in wrist measurement was associated with the presence of atherosclerotic disease (odds ratio: 3.64; p = 0.001).

Conclusions: In this prospective study of patients with ACS, the use of photometry through a device on the wrist of patients showed accuracy in predicting elevated TI-us values.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of

Original Title: A Novel Breakthrough In Wrist-Worn Transdermal Troponin-I-Sensor Assessment For Acute Myocardial Infarction.

Reference: Presentado por Partho Sengupta en Late Breaking Trials del ACC.23/WCC Marzo 4-6, 2023, en New Orleans.

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology